Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−84.58 MXN
−7.85 B MXN
1.32 B MXN
91.27 M
About Beam Therapeutics Inc.
Sector
Industry
CEO
John Evans
Website
Headquarters
Cambridge
Founded
2017
ISIN
US07373V1052
FIGI
BBG0166VGZM1
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of BEAM is 500.00 MXN — it has increased by 0.60% in the past 24 hours. Watch Beam Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange Beam Therapeutics, Inc. stocks are traded under the ticker BEAM.
BEAM stock has risen by 1.21% compared to the previous week, the month change is a 29.20% rise, over the last year Beam Therapeutics, Inc. has showed a 11.41% increase.
We've gathered analysts' opinions on Beam Therapeutics, Inc. future price: according to them, BEAM price has a max estimate of 1,478.20 MXN and a min estimate of 369.55 MXN. Watch BEAM chart and read a more detailed Beam Therapeutics, Inc. stock forecast: see what analysts think of Beam Therapeutics, Inc. and suggest that you do with its stocks.
BEAM reached its all-time high on Feb 16, 2023 with the price of 806.00 MXN, and its all-time low was 309.00 MXN and was reached on Aug 26, 2025. View more price dynamics on BEAM chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
BEAM stock is 0.60% volatile and has beta coefficient of 2.09. Track Beam Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Beam Therapeutics, Inc. there?
Today Beam Therapeutics, Inc. has the market capitalization of 50.78 B, it has increased by 6.77% over the last week.
Yes, you can track Beam Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Beam Therapeutics, Inc. is going to release the next earnings report on Nov 10, 2025. Keep track of upcoming events with our Earnings Calendar.
BEAM earnings for the last quarter are −18.76 MXN per share, whereas the estimation was −20.87 MXN resulting in a 10.12% surprise. The estimated earnings for the next quarter are −19.03 MXN per share. See more details about Beam Therapeutics, Inc. earnings.
Beam Therapeutics, Inc. revenue for the last quarter amounts to 158.81 M MXN, despite the estimated figure of 239.49 M MXN. In the next quarter, revenue is expected to reach 207.83 M MXN.
BEAM net income for the last quarter is −1.92 B MXN, while the quarter before that showed −2.24 B MXN of net income which accounts for 14.29% change. Track more Beam Therapeutics, Inc. financial stats to get the full picture.
No, BEAM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 17, 2025, the company has 483 employees. See our rating of the largest employees — is Beam Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Beam Therapeutics, Inc. EBITDA is −7.95 B MXN, and current EBITDA margin is −619.73%. See more stats in Beam Therapeutics, Inc. financial statements.
Like other stocks, BEAM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Beam Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Beam Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Beam Therapeutics, Inc. stock shows the strong buy signal. See more of Beam Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.